Plumb Pharmaceuticals

Plumb Pharmaceuticals is a specialty biotechnology company focused on developing long-acting, extended-release formulations of existing medications to improve patient adherence and clinical outcomes. The company utilizes its proprietary Plumb Platform, a polymer-based drug delivery technology, to create injectable treatments that release therapeutic levels of medication over several months. Its lead program is a multi-month formulation of naltrexone designed to treat opioid use disorder (OUD) and alcohol use disorder. By significantly extending the dosing interval, Plumb aims to reduce the burden of frequent injections and minimize the risk of relapse in patients struggling with addiction. The company is a spin-out from the University of Wisconsin-Madison and is currently advancing its lead candidate through IND-enabling studies.